ZK512.4 Antibody

What is ZK512.4 and its function in C. elegans?

ZK512.4 in C. elegans encodes the Signal recognition particle 9 kDa protein (SRP9), which forms part of the signal recognition particle machinery involved in protein targeting to the endoplasmic reticulum. This component is critical for proper protein secretion and membrane protein insertion within nematode cells. The protein shares functional homology with human SRP9, operating within the conserved protein translocation pathway across eukaryotes. Studies with ZK512.4 antibodies can help elucidate protein localization patterns in different tissues and developmental stages of C. elegans.

What applications are most suitable for ZK512.4 antibody in C. elegans research?

ZK512.4 antibody is particularly valuable for techniques including Western blotting, immunoprecipitation, immunofluorescence, and ELISA in C. elegans research. For Western blot applications, researchers typically use whole worm lysates to detect the approximately 9 kDa band corresponding to the SRP9 protein. Immunoprecipitation experiments can reveal protein-protein interactions involving ZK512.4/SRP9, similar to the methodology used for SEC-16 and TFG-1 interaction studies in C. elegans . Immunofluorescence applications allow visualization of subcellular localization, particularly in the secretory pathway structures.

What are the optimal fixation protocols for immunohistochemistry with ZK512.4 antibody?

For optimal immunohistochemistry results with ZK512.4 antibody in C. elegans, a paraformaldehyde-based fixation protocol is recommended. Effective protocols involve fixing synchronized worm populations with 4% paraformaldehyde for 30-45 minutes at room temperature, followed by permeabilization with either acetone (-20°C, 5 minutes) or 0.1% Triton X-100. This approach preserves protein epitopes while facilitating antibody penetration into tissues. For embryos and gonads, methanol fixation (-20°C, 5 minutes) following permeabilization can enhance antigen accessibility. When working with dissected tissues, the fixation time should be reduced to 15-20 minutes to prevent epitope masking, similar to protocols used for other secretory pathway proteins in C. elegans .

How can I design co-immunoprecipitation experiments to identify ZK512.4 interaction partners?

To identify ZK512.4/SRP9 interaction partners in C. elegans, design co-immunoprecipitation experiments using approaches similar to those employed for SEC-16 protein studies. Begin by preparing detergent-solubilized embryo or whole worm extracts using a lysis buffer containing 1% NP-40 or 0.5% CHAPS, 150mM NaCl, 50mM Tris-HCl pH 7.5, and protease inhibitor cocktail. Incubate the clarified lysate with ZK512.4 antibody (5-10μg) coupled to protein A/G beads overnight at 4°C. After thorough washing, analyze co-precipitating proteins by SDS-PAGE followed by mass spectrometry to identify novel interaction partners. Validate findings using reciprocal co-IP experiments and independent methods such as proximity labeling. This approach successfully identified 19 interaction partners for SEC-16 in previous studies .

What are the appropriate controls for ZK512.4 knockdown verification experiments?

When conducting ZK512.4 knockdown experiments using RNAi or CRISPR-Cas9 technologies, implement a multi-level validation strategy. First, include a non-targeting control RNAi or a scrambled guide RNA as a negative control. Second, use at least two independent RNAi constructs or guide RNAs targeting different regions of ZK512.4 to confirm specificity. Third, verify knockdown efficiency at both mRNA level (qRT-PCR) and protein level (Western blot with ZK512.4 antibody). Fourth, include a known phenotype control—such as RNAi against essential genes like SEC-16 or SEC-12—that produces recognizable defects in embryo production . Finally, perform rescue experiments by expressing RNAi-resistant ZK512.4 variants to confirm phenotype specificity.

How can I optimize subcellular fractionation to study ZK512.4 distribution in secretory pathway compartments?

For detailed analysis of ZK512.4/SRP9 distribution across secretory pathway compartments, employ a step-wise subcellular fractionation protocol. Begin by homogenizing synchronized worm populations in isotonic buffer (250mM sucrose, 10mM HEPES pH 7.4, 1mM EDTA) using a Dounce homogenizer with 15-20 gentle strokes. Centrifuge the homogenate at 1,000g for 10 minutes to remove nuclei and cell debris, then process the supernatant through differential centrifugation: 10,000g (10 min) for mitochondria and large organelles, 100,000g (1 hour) for microsomes containing ER and Golgi membranes. For greater resolution, subject the 100,000g microsomal fraction to sucrose density gradient centrifugation (0.8M-2.0M sucrose) to separate ER, ERGIC, and Golgi fractions. Analyze each fraction by Western blotting using ZK512.4 antibody alongside markers for distinct compartments (SEC-16 for ER exit sites, TFG-1 for ER-Golgi interface) .

How does ZK512.4 antibody performance compare between whole-mount immunofluorescence and dissected tissue preparations?

ZK512.4 antibody exhibits distinct performance profiles in whole-mount versus dissected C. elegans preparations. In whole-mount preparations, the cuticle creates penetration barriers that can limit antibody accessibility, requiring extended incubation times (overnight at 4°C with 1:100-1:200 dilution) and more aggressive permeabilization (0.5% Triton X-100 or 0.1% SDS). In contrast, dissected tissues (particularly gonads and intestines) provide superior antibody access, allowing shorter incubation periods (4-6 hours at room temperature) with milder permeabilization (0.1% Triton X-100) and more dilute antibody concentrations (1:200-1:500). The signal-to-noise ratio is typically 2-3 fold higher in dissected preparations, making them preferable for high-resolution imaging of subcellular structures. This behavior is consistent with observations for other antibodies targeting secretory pathway proteins in C. elegans .

What strategies minimize background when using ZK512.4 antibody in immunostaining?

To minimize background when using ZK512.4 antibody for immunostaining C. elegans tissues, implement a comprehensive optimization strategy. First, include a pre-adsorption step by incubating the diluted antibody with acetone powder prepared from ZK512.4 null mutant worms (if available) or from a different species (such as Drosophila) for 1 hour at room temperature. Second, optimize blocking conditions by testing various blockers (5% BSA, 10% goat serum, commercial blockers) in combination with extended blocking times (2-3 hours at room temperature). Third, add 0.1% Tween-20 to all antibody dilution and wash buffers. Fourth, include competitive peptide controls using the peptide sequence used for antibody generation. Fifth, employ sample-specific background reduction techniques such as treating with 0.1% sodium borohydride for 10 minutes before blocking to reduce autofluorescence, particularly in the gut region. Comparable approaches have yielded high signal-to-noise ratios for TFG-1 and SEC-16 antibodies in previous studies .

What are the optimal protein extraction conditions for preserving ZK512.4 epitopes in Western blot applications?

For optimal preservation of ZK512.4/SRP9 epitopes during protein extraction for Western blot applications, a carefully calibrated lysis protocol is essential. Use a modified RIPA buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1mM EDTA) supplemented with both protease inhibitor cocktail and phosphatase inhibitors. Mechanical disruption should be performed by bead-beating frozen worm pellets for 30-second intervals with 30-second cooling periods to prevent heat denaturation. After clarification (14,000g, 15 minutes, 4°C), add reducing sample buffer and heat samples to 70°C for 10 minutes rather than boiling, as boiling can cause aggregation of membrane-associated proteins like SRP9. This moderate heating approach prevents epitope masking while ensuring sufficient denaturation for accurate size determination on SDS-PAGE, similar to the optimized approach used for analyzing TFG-1 samples in previous research .

How can I distinguish between specific and non-specific signals when interpreting ZK512.4 antibody results?

To definitively distinguish between specific and non-specific signals in ZK512.4 antibody experiments, employ multiple validation approaches. First, include genetic controls such as ZK512.4 null mutants or RNAi-depleted samples, which should show significant reduction or absence of the specific signal. Second, perform peptide competition assays by pre-incubating the antibody with excess immunizing peptide (100-fold molar excess), which should eliminate specific signals while leaving non-specific binding intact. Third, validate findings using an independent antibody raised against a different epitope of ZK512.4 or a tagged version of the protein. Fourth, cross-reference localization data with other techniques such as in situ hybridization or fluorescent reporter fusions. Finally, benchmark staining patterns against predicted subcellular localization based on protein function—SRP9 should predominantly localize to the cytoplasm and ER-associated regions. This multi-layered validation approach is consistent with rigorous antibody validation strategies employed for other C. elegans proteins .

What explains the discrepancy between predicted and observed molecular weights of ZK512.4 in Western blots?

Discrepancies between predicted and observed molecular weights of ZK512.4/SRP9 in Western blots can stem from multiple factors. First, post-translational modifications such as phosphorylation, ubiquitination, or SUMOylation can increase apparent molecular weight. Second, the hydrophobic regions or structural motifs in SRP9 may bind disproportionate amounts of SDS, altering migration patterns. Third, incomplete denaturation of protein complexes can occur if sample preparation conditions are suboptimal. To address these issues, perform parallel analyses with different sample preparation methods: standard reducing conditions, non-reducing conditions, and varied heating temperatures (37°C, 70°C, and 95°C). Additionally, treat samples with phosphatase and/or deglycosylation enzymes to assess the contribution of these modifications. Similar mobility shifts have been observed with TFG-1, which migrates at approximately 75 kDa despite a predicted size of 49.8 kDa, and recombinant TFG-1 exhibits comparable slow migration patterns on SDS-PAGE .

How should I interpret changes in ZK512.4 localization patterns following secretory pathway stress?

When interpreting changes in ZK512.4/SRP9 localization patterns following secretory pathway stress, consider the integrated response of the protein sorting machinery. Under normal conditions, ZK512.4/SRP9 typically shows diffuse cytoplasmic distribution with enrichment at ER membranes. During ER stress (induced by tunicamycin or thapsigargin), expect redistribution with increased punctate accumulation at ER exit sites, potentially colocalizing with SEC-16. In protein transport blockade scenarios (Brefeldin A treatment), anticipate accumulation in ER-derived structures as anterograde transport is inhibited. Quantitative analysis should measure both intensity changes and spatial redistribution using parameters such as puncta number, size, intensity, and colocalization coefficients with organelle markers. Compare these changes to known stress response patterns of other secretory proteins like TFG-1, which forms a matrix-like structure at ER exit sites that extends to the ERGIC region, as demonstrated by immuno-gold electron microscopy .

How can I combine ZK512.4 antibody staining with live imaging techniques to study protein dynamics?

To combine ZK512.4 antibody staining with live imaging for dynamic studies of SRP9 behavior, implement a correlative live-fixed imaging approach. Begin by observing living worms expressing fluorescent markers for organelles of interest (such as ER-targeted GFP) using spinning disk confocal microscopy. Record dynamic behaviors for 5-10 minutes with 3-5 second intervals. Immediately fix the same specimen using rapid fixation (4% paraformaldehyde injection into the imaging chamber) and process for ZK512.4 immunostaining. Realign the fixed sample to match the live imaging field using registration algorithms and anatomical landmarks. This approach allows correlation between dynamic events observed in live imaging and the precise localization of endogenous ZK512.4/SRP9. For even more precise temporal control, consider using a modified protocol similar to that employed for Alexa Fluor 555-labeled antibodies against aquaporin-4, which enables visualization of binding dynamics in live cells .

What experimental design would effectively determine if ZK512.4 function is conserved between C. elegans and human orthologs?

To determine functional conservation between C. elegans ZK512.4/SRP9 and its human ortholog, design a multi-phase comparative study. First, conduct detailed sequence analysis to identify conserved domains and critical residues. Second, perform rescue experiments by expressing human SRP9 in ZK512.4-deficient worms to assess functional complementation. Third, analyze protein interaction networks by immunoprecipitating both C. elegans and human proteins and comparing interactomes through mass spectrometry. Fourth, conduct subcellular localization studies using species-specific antibodies to determine if localization patterns are conserved. Fifth, perform domain-swapping experiments where conserved functional domains are exchanged between species variants to identify critical regions for function. This experimental approach parallels successful conservation studies of TFG protein, where the N-terminal domain of human TFG was shown to interact with Sec16 in an evolutionarily conserved manner, as demonstrated through co-immunoprecipitation experiments with mCherry-tagged Sec16B and GFP-tagged TFG constructs .

How can proximity labeling techniques be combined with ZK512.4 antibody to map protein interaction networks?

To map ZK512.4/SRP9 protein interaction networks using proximity labeling, design a BioID or APEX2-based approach complemented with ZK512.4 antibody validation. Generate transgenic C. elegans expressing ZK512.4 fused to either BioID2 (a biotin ligase) or APEX2 (an ascorbate peroxidase) under native regulatory elements. For BioID experiments, supplement worm growth medium with biotin (50μM) for 24-48 hours; for APEX2, briefly expose worms to biotin-phenol (500μM) followed by H₂O₂ (1mM) for 1 minute. After crosslinking and lysis, capture biotinylated proteins using streptavidin beads and identify them via mass spectrometry. Validate proximity labeling results by immunoprecipitation with ZK512.4 antibody and immunoblotting for selected candidates. For spatial resolution enhancement, perform immunofluorescence using ZK512.4 antibody combined with streptavidin-fluorophore to map biotinylation patterns relative to organelle markers. This integrated approach provides both systematic discovery of interaction partners and spatial context for these interactions, similar to the comprehensive strategy used to identify SEC-16 interaction partners in C. elegans .